Last reviewed · How we verify

Poly IC — Competitive Intelligence Brief

Poly IC (Poly IC) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TLR3 agonist / Immunostimulant. Area: Immunology / Oncology.

marketed TLR3 agonist / Immunostimulant TLR3 (Toll-like receptor 3) Immunology / Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Poly IC (Poly IC) — Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Poly IC is a synthetic double-stranded RNA analog that activates innate immune responses through toll-like receptor 3 (TLR3) signaling.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Poly IC TARGET Poly IC Union Hospital, Tongji Medical College, Huazhong University of Science and Technology marketed TLR3 agonist / Immunostimulant TLR3 (Toll-like receptor 3)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TLR3 agonist / Immunostimulant class)

  1. Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Poly IC — Competitive Intelligence Brief. https://druglandscape.com/ci/poly-ic. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: